Literature DB >> 28774196

The Clinical Utility of the Heparin Neutralization Assay in the Diagnosis of Heparin-Induced Thrombocytopenia.

Gang Zheng1, Michael B Streiff2, Clifford M Takemoto3, Jennifer Bynum1, Elise Gelwan1, Jayesh Jani1, Danielle Judge1, Thomas S Kickler1,2.   

Abstract

Heparin-induced thrombocytopenia (HIT) remains diagnostically challenging. Immunoassays including PF4/heparin enzyme-linked immunosorbent assay (ELISA) have high sensitivity but low specificity. Whether the heparin neutralization assay (HNA) improves the diagnostic accuracy of the PF4/heparin ELISA for HIT is uncertain. In this study, to assess its clinical utility and evaluate whether it improves the diagnostic accuracy for HIT, we implemented HNA in conjunction with PF4/heparin ELISA over a 1-year period. A total of 1194 patient samples were submitted to the laboratory for testing from December 2015 to November 2016. Heparin neutralization assay alone is a poor predictor for HIT, but it has high negative predictive value (NPV): Cases with %inhibition <70% are always negative for serotonin release assay. It improves the diagnostic positive predictive value (PPV) of ELISA without compromising sensitivity: ELISA optical density (OD) ≥1.4 alone has a sensitivity of 88% (14/16) and a PPV of 61% (14/23); with HNA %inhibition ≥70%, the sensitivity remains 88% (14/16) and PPV is 82% (14/17). 4Ts score correlates with ELISA OD and predicts HIT; the predictive accuracy of 4Ts score is further improved by HNA. Interestingly, HNA %inhibition of <70% correlates with low 4Ts scores. Based on its high NPV, HNA has the potential to facilitate more timely and accurate HIT diagnosis.

Entities:  

Keywords:  4Ts score; PF4/heparin ELISA; heparin neutralization assay; heparin-induced thrombocytopenia; serotonin release assay

Mesh:

Substances:

Year:  2017        PMID: 28774196      PMCID: PMC6714880          DOI: 10.1177/1076029617721013

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  35 in total

1.  Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings.

Authors:  G K Lo; D Juhl; T E Warkentin; C S Sigouin; P Eichler; A Greinacher
Journal:  J Thromb Haemost       Date:  2006-04       Impact factor: 5.824

Review 2.  Heparin-induced thrombocytopenia: pathogenesis and management.

Authors:  Theodore E Warkentin
Journal:  Br J Haematol       Date:  2003-05       Impact factor: 6.998

3.  Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients.

Authors:  Andreas Greinacher; Beate Farner; Hartmut Kroll; Thomas Kohlmann; Theodore E Warkentin; Petra Eichler
Journal:  Thromb Haemost       Date:  2005-07       Impact factor: 5.249

Review 4.  Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models.

Authors:  Kelly H Zou; A James O'Malley; Laura Mauri
Journal:  Circulation       Date:  2007-02-06       Impact factor: 29.690

5.  Usefulness of optical density values from heparin-platelet factor 4 antibody testing and probability scoring models to diagnose heparin-induced thrombocytopenia.

Authors:  Kim A Janatpour; Robert C Gosselin; William E Dager; Andrew Lee; John T Owings; Jufen Zhou; Ted Wun
Journal:  Am J Clin Pathol       Date:  2007-03       Impact factor: 2.493

6.  Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range.

Authors:  A Greinacher; P Eichler; N Lubenow; H Kwasny; M Luz
Journal:  Blood       Date:  2000-08-01       Impact factor: 22.113

7.  Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia.

Authors:  D E Wallis; D L Workman; B E Lewis; L Steen; R Pifarre; J F Moran
Journal:  Am J Med       Date:  1999-06       Impact factor: 4.965

Review 8.  The pathophysiology of immune-mediated heparin-induced thrombocytopenia.

Authors:  Robert F Reilly
Journal:  Semin Dial       Date:  2003 Jan-Feb       Impact factor: 3.455

9.  What is the potential for overdiagnosis of heparin-induced thrombocytopenia?

Authors:  Gregory K Lo; Christopher S Sigouin; Theodore E Warkentin
Journal:  Am J Hematol       Date:  2007-12       Impact factor: 10.047

10.  Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy.

Authors:  Gustavo B F Oliveira; Eric M Crespo; Richard C Becker; Emily F Honeycutt; Charles S Abrams; Kevin J Anstrom; Peter B Berger; Linda D Davidson-Ray; Eric L Eisenstein; Neal S Kleiman; David J Moliterno; Stephan Moll; Lawrence Rice; Jo E Rodgers; Steven R Steinhubl; Victor F Tapson; E Magnus Ohman; Christopher B Granger
Journal:  Arch Intern Med       Date:  2008-01-14
View more
  1 in total

1.  Indeterminate serotonin release assays are associated with a high mortality rate.

Authors:  Shawn Jindal; Christopher Leyton; Fred Cohen; Morayma Reyes Gil; Henny Billett
Journal:  Res Pract Thromb Haemost       Date:  2022-06-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.